Research projects from three biopharmaceutical companies in the United States comprise the 2013 second half (2H 2013) of The Michael J. Fox Foundation for Parkinson’s Research (MJFF) Partnering Program. Among the most promising in the MJFF portfolio, Partnering Program participants’ research projects are presented directly to industry groups who may wish to invest in further development of the project. By connecting industry leaders with those studies ripe for investment, the Foundation aims to drive forward promising research in Parkinson’s disease (PD) through the pipeline of drug development and eventually into patients’ hands.

Selected for the 2H 2013 MJFF Partnering Program are:

• Eboo Pharmaceutical Inc.’s development of a unique series of compounds that have the potential to alleviate PD symptoms and mitigate the motor complications (dyskinesia) related to dopamine replacement therapy
• FPRT Bio Inc.’s study of XPro1595, which “turns off” inflammation to stop the loss of dopaminergic neurons and prevents disease progression
• MentiNova Inc.’s repurposing of a compound developed for pain management for the treatment of levodopa-induced dyskinesia and other hyperkinetic movement disorders

To read more on the selected participants, and all MJFF awardees chosen for the Partnering Program thus far, visit the Partnering Program Web page.